BioInvent International AB (publ) (STO:BINV)

Market Cap	1.53B -3.5%
Revenue (ttm)	226.50M +406.9%
Net Income	-332.86M
EPS	-5.06
Shares Out	65.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	159,098
Average Volume	116,740
Open	22.90
Previous Close	23.25
Day's Range	21.50 - 22.90
52-Week Range	21.50 - 41.60
Beta	-0.03
RSI	26.15
Earnings Date	Feb 26, 2026

About STO:BINV

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-19...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 109
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BINV

Financial Performance

In 2025, STO:BINV's revenue was 226.50 million, an increase of 406.86% compared to the previous year's 44.69 million. Losses were -332.86 million, -22.48% less than in 2024.